Treatments and Solutions¶
This page focuses on the main solution categories parents may encounter in childhood eczema care. A "solution" can mean a prescription medicine, a moisturiser routine, a supportive treatment, or a home remedy that families are considering.
If your question is "which cream or ingredient made my child sting or improve?", start with Products and Substances. If your question is "what kind of treatment is this and when is it usually used?", this page is the right starting point.
The main categories¶
It helps to group eczema solutions into:
- baseline barrier care
- flare-control medicines
- steroid-sparing prescription options
- supportive treatments around flares
- stronger specialist treatments
- home remedies and low-evidence ideas
This makes it easier to compare options fairly.
Baseline barrier care¶
For most children, the base of care is still:
- regular moisturiser use
- short lukewarm bathing
- gentle cleansers
- avoiding known irritants
These may sound simple, but they are the foundation that everything else sits on.
Emollient brands widely available in Greek and European pharmacies include Eucerin AtopiControl, Bioderma Atoderm, A-Derma Exomega Control, CeraVe, Cetaphil Restoraderm, Avène XeraCalm, La Roche-Posay Lipikar, and Mustela Stelatopia. All are available without a prescription. For a full product comparison by substance, see Pharmacy Products.
Flare-control medicines¶
Topical corticosteroids¶
These are the main prescription treatment for active eczema flares. All require a prescription in Greece.
Key ideas:
- they are usually the first-line anti-inflammatory treatment
- different strengths are used for different body areas and ages
- face and neck usually need milder options; more potent steroids are reserved for thicker skin areas (hands, elbows, knees) under medical guidance
- they work best when started early and used correctly
- proactive maintenance therapy (applying a mild-to-moderate TCS or calcineurin inhibitor to previously affected skin 2–3 times per week, even when calm) significantly reduces flare frequency and is supported by meta-analysis (Schmitt et al., Br J Dermatol, 2011) and current NICE/EuroGuiDerm guidelines
One of the biggest practical problems in eczema care is not steroid overuse, but steroid avoidance because of fear.
European brands available in Greek pharmacies include hydrocortisone generics (mild), Locoid (hydrocortisone butyrate, moderate), Advantan (methylprednisolone aceponate, potent, once daily), and Elocon (mometasone furoate, potent, once daily). See Pharmacy Products for the full table with potency classes and prescribing notes.
Steroid-sparing prescription options¶
These options become especially relevant when:
- the child flares often
- eczema is in sensitive areas
- parents want a maintenance plan that does not rely only on steroids
- usual flare treatment is not enough
Practical comparison¶
| Option | EU/Greece availability | Practical takeaway |
|---|---|---|
| Tacrolimus ointment (Protopic) / pimecrolimus cream (Elidel) | Available in Europe and Greece — prescription required | Steroid-sparing options often used on face, eyelids, folds, or for maintenance; do not thin skin; stinging is common at first. Protopic 0.03% for children ≥ 2 years; Protopic 0.1% for adults ≥ 16 years. |
| Crisaborole 2% ointment (Staquis/Eucrisa) | Not available in Europe — EMA authorisation withdrawn January 2022 | Approved from 3 months in the US; families seeing US sources should know it is not a European option. |
| Roflumilast 0.15% cream (Zoryve) | Not available in Europe — no EMA approval as of April 2026 | FDA-approved from 2 years (0.15%) and ages 2-5 (0.05%); not yet submitted to EMA. |
| Ruxolitinib 1.5% cream (Opzelura) | Not approved in Europe for eczema — EMA approved for vitiligo only | FDA-approved for eczema from age 12 in the US; in Europe, Opzelura is authorised for vitiligo only. |
| Tapinarof 1% cream (VTAMA) | Not available in Europe — no EMA approval as of April 2026 | FDA approved December 2024 from age 2; not yet available in Greece. |
See Pharmacy Products for detailed product names, prescription status, and what is and is not available in European pharmacies.
These do not automatically replace older treatments, but they are important options in the expanding treatment landscape.
Supportive treatments used during worse periods¶
Bleach baths¶
- may help some children, especially when bacterial overgrowth seems to be part of the problem
- need exact dilution and care
- can irritate if used badly or on very damaged skin
Wet wraps¶
- may help during moderate or severe flares
- increase hydration and can strengthen the effect of topical treatment
- need care because occlusion also increases some risks
Topical antimicrobials¶
These are not routine eczema treatment when there are no signs of infection.
If there is weeping, crusting, fever, pain, or fast worsening, go to When to Get Help rather than treating it as a simple flare at home.
Oral antibiotics¶
- these are not routine eczema medicines and are not needed for most flares
- they become more relevant when bacterial infection looks widespread, severe, or the child seems unwell
- some antibiotic courses given during an eczema period may actually be for a separate ear, throat, sinus, chest, or dental infection, not for the eczema itself
- if a child keeps needing oral antibiotics for "infected eczema", ask when to do a skin swab, whether decolonization should be discussed, and whether the diagnosis needs a re-check
For this child's history, the oral antibiotics Ceclor (cefaclor), Amoxil (amoxicillin), and Augmentin (co-amoxiclav) should be treated mainly as infection-history markers that need interpretation, not as standing eczema products. See Available Products & Treatment Plan for the episode-specific analysis.
Stronger specialist treatments¶
When eczema is moderate to severe and not controlled with topical care, specialist-level options may be discussed.
Currently available biologics and systemic therapies¶
| Treatment | EU brand name | Type | Age | Practical takeaway |
|---|---|---|---|---|
| Dupilumab | Dupixent (Sanofi) | Biologic (anti-IL-4Rα) | From 6 months | EMA approved; most established biologic for pediatric AD; prescription and specialist initiation required |
| Tralokinumab | Adtralza (LEO Pharma) | Biologic (anti-IL-13) | From 12 years | EMA approved 2021; specialist prescription |
| Lebrikizumab | Ebglyss (Lilly) | Biologic (anti-IL-13) | From 12 years | EMA approved November 2023; specialist prescription |
| Nemolizumab | Nemluvio / Mitchga | Biologic (anti-IL-31Rα) | From 12 years (2026 data in ages 2-11) | EMA approved 2024; targets itch directly; specialist prescription |
| Upadacitinib | Rinvoq (AbbVie) | Oral JAK inhibitor | From 12 years | EMA approved; oral option for adolescents; specialist prescription |
| Abrocitinib | Cibinqo (Pfizer) | Oral JAK inhibitor | From 12 years | EMA approved; oral JAK inhibitor for adolescents; specialist prescription |
| Baricitinib | Olumiant (Eli Lilly) | Oral JAK inhibitor | From age 2 (Europe) | EMA approved for AD from age 2 (October 2023); not approved for AD in the US; specialist prescription |
See Pharmacy Products for a full table of EU approval status and brand names for specialist treatments.
Parents do not need to memorise every name. The important point is that treatment options now go far beyond steroid creams alone.
2026 pipeline: what may be coming¶
The AAD 2026 Annual Meeting (March 2026) presented late-breaking data on several new treatments. None of these are approved yet, but they signal where eczema treatment is heading:
| Treatment | What it is | Why it matters for families |
|---|---|---|
| Amlitelimab (Sanofi) | Anti-OX40L antibody | Dosing as infrequent as every 12 weeks; phase 3 positive; regulatory submissions planned H2 2026 |
| Tilrekimig (Pfizer) | First trispecific antibody (IL-4 + IL-13 + TSLP) | Blocks three inflammatory drivers at once; once monthly; phase 3 starting 2026 |
| KT-621 (Kymera) | Oral STAT6 degrader | An oral pill that may match biologic-level efficacy; FDA Fast Track; phase 2b ongoing |
| Rademikibart | Anti-IL-4Rα antibody | 87% clear/almost clear skin at 52 weeks in phase 3; lower conjunctivitis than similar drugs |
| Rezpegaldesleukin (Nektar) | T-regulatory cell therapy | Boosts the body's own immune regulation; quarterly dosing possible; phase 3 planned Q2 2026 |
| ZORYVE for infants (Arcutis) | Roflumilast cream 0.05% | Phase 2 data in infants 3-24 months; 58% achieved EASI-75; NDA submission expected Q2 2026 |
For families, the practical meaning is:
- More options at every age, including infants from 3 months
- Less-frequent dosing (monthly or quarterly instead of every 2 weeks)
- Oral alternatives to injections may become available
- Itch-first targeting (nemolizumab addresses what many families say is the worst symptom)
Home remedies and low-evidence ideas¶
Some ideas discussed online have at least some plausibility, but they should not be treated as proven.
| Idea | Practical takeaway |
|---|---|
| Hypochlorous acid sprays | Sometimes used for weepy or infection-prone skin; promising rationale, but better paediatric eczema data are still limited. |
| Black tea compresses | Sometimes discussed for facial eczema; avoid on obviously infected skin. |
| Coconut oil | Helps some children, but can irritate others or trigger folliculitis; do not assume "natural" means safe. |
| Dead Sea salt / magnesium-rich baths | May help some children, but can sting on broken skin. |
These ideas may still be worth documenting carefully if tried, but they need more caution than standard care.
For incident-style reports, parent anecdotes, and specific low-evidence stories, use Incidents and Anecdotes.
Homeopathy is explored separately in Homeopathy and belongs to that non-core track, not the standard treatment ladder.
Solutions that need particular caution¶
Some approaches are more likely to create harm or confusion:
- DIY chemical preparations
- unsupervised elimination diets
- no-moisture treatment in a child
- repeated switching between products before a clear trial period
What to document when trying a solution¶
Whenever a new solution is used, it helps to record:
- what category of solution it was
- the exact product name if there was one
- the main substance or ingredient if known
- where it was used
- how often it was used
- what happened afterward
This is how families move from "we tried things" to "we understand patterns." For practical logging structure, see Triggers and Tracking.
Key references¶
- AAP. "Atopic Dermatitis: Clinical Practice Guideline." Pediatrics, 2025.
- EuroGuiDerm. "European guideline on atopic eczema — systemic therapy update." J Eur Acad Dermatol Venereol, 2024.
- NICE CG57. "Atopic eczema in under 12s: diagnosis and management." Updated 2023.
- NICE NG190. "Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing." Updated 2024.
- EMA — Dupixent (dupilumab): ema.europa.eu
- EMA — Adtralza (tralokinumab): ema.europa.eu
- EMA — Ebglyss (lebrikizumab): ema.europa.eu
- EMA — Olumiant (baricitinib) new AD indication for children from age 2: ema.europa.eu
- Langan SM, Irvine AD, Weidinger S. "Atopic dermatitis." Lancet 396:345–360, 2020.